Vandetanib [Caprelsa] - Caprelsa 300mg |millionhealthpharma



Vandetanib is sold under the brand name Caprelsa 300mg, Caprelsa 300mg tablet consist of broad spectrum, orally available kinase inhibitor that targets mainly tyrosine kinases, containing vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with IC50 values in the nanomolar range. Caprelsa 300mg tablet which is used as prescription drug under the guidance of medical practioners


Indicated for the therapy of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.


Vandetanib, Caprelsa 300mg tablet belongs to type of targeted therapy called a tyrosine kinase inhibitor. A kinase is an enzyme which helps to cell growth. This means it mechanism by targeting receptors present on the cancer cells. Vandetanib aims epidermal growth factor (EGFR) and vascular endothelial growth factor receptors (VEGF). It stops tumor growth and the development of a blood supply to the tumor (angiogenesis).

Caprelsa 300mg

Ingredients : Vandetanib
Strength : 300mg
Package : 30 film tablets


Absorption: Duration to maximum plasma level is 6 hr (range 4-10hr)and steady state is 3 months
Distribution: Bounding of plasma protein is 90% and volume of distribution is 7450L
Metabolism: Caprelsa 300mg tablet is metabolized by CYP3A4
Elimination: The drug elimination through feces 44% and via urine collection period of 21 day after single dose.
Half-life 19 days


The Caprelsa 300mg prescribed dose for medullary thyroid cancer is 300mg administrated orally once daily until disease progression or unacceptable toxicity occurs. Avoid the tablets crushing, disperse the tablet in 2 ounces of water by stirring 10 minutes approximately. Be cautious, avoid use other liquids for dispersion and swallow the medicine soon after dispersion, if any remaining residue with 4 additional ounces of water and swallow. Th dispersion liquid can be administrated via nasogastric or gastrostomy tubes.

                  Caprelsa 300 mg



The drug Caprelsa 300mg tablet using for treatment which will have Effective CYP3A4 inducers decreased exposure to Vandetanib by up to 40%; however, no clinically significant effect on exposure to Vandetanib was resulted in the presence of the effective CYP3A4 inhibitors. While on treatment with Caprelsa 300mg producing Fatal skin reactions, involving with Stevens-Johnson syndrome and serious toxic epidermal necrolysis resulted; systemic treatment such as corticosteroids may be required; permanently blocks therapy for severe skin reactions. While on treatment with Caprelsa 300mg will produce Interstitial lung disease (ILD), causes in death has been reported; interfere with Vandetanib and examine unexplained Dyspnea, cough, and fever; applicable measures should be taken for ILD When on treatment with Caprelsa 300mg will causes Ischemic cerebrovascular events, haemorrhage, heart failure, diarrhea, hypothyroidism, hypertension, and reversible posterior leukoencephalopathy syndrome,. Due to the drug Caprelsa 300mg tablet can cause fetal harm when administered to pregnant women; advise not to become pregnancy while getting Caprelsa  300mg and for 4 months following treatment.


Caprelsa 300mg tablet has some side effects as follows :
Headache, Fatigue, Kidney problems, Dry skin, Vomiting, Weakness, Irregular heart beat,Difficulty sleeping, Low blood sugar, Abdominal pain, Poor appetite, Weight loss, Diarrhea, Rash, Elevated Liver Enzymes (ALT), Low calcium levels, Acne, High blood pressure, Nausea, Low white blood cell count, Photosensitivity (sensitivity to sunlight), Bleeding, Anemia, Liver tests increased (bilirubin), Itching, Heartburn, Cough, Upper respiratory infection, Depression.

Caprelsa 300mg


Pregnancy category D
Caprelsa 300mg tablet is embryotoxic and fetotoxic, because of pharmacological action treatment will causes harm to fetal when administered to a pregnant woman


During treatment Advise females not to breastfeed for 4 months after final dose.


Caprelsa 300mg tablets should be stored at 25°C.


If dose is missed to take, then administer the dose immediate before reach of next dose time or swap the missed dose and follow the normal schedule. Do not take missed dose within 12 hours of the next dose.
Should consult the doctor about missed dose and overdose.

contact us

MAIL ID           : 
PHONE NO     :       +91-9940472902
WEBSITE        :


Popular Posts